IP Library Granted Patent US 9,551,009
Granted Patent B2
US 9,551,009 · App. 14/354,331 · Granted Jan 24, 2017

Transcription unit and use thereof in expression vectors

Inventors: Alexandre Fontayne (La Madeleine, FR); Francois Coutard (Ales, FR)
Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C12N15/85C07K16/2869C07K16/2887C07K16/2896C12P21/00C12N2830/15C12N2830/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,551,009
App. No.
14/354,331
Granted
Jan 24, 2017
Kind
B2
Abstract

A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.

Claims (14)

1. A transcription unit comprising a polynucleotide comprising the following regulatory elements:

a. the hCMVie virus enhancer, said enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleic acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and having transcription activation activity,

b. the promoter region of Cyclin-Dependent Kinase 9 (CDK9), said promoter region haying the nucleotide sequence SEQ ID NO: 2, or a nucleic acid having at least 70% sequence identity with the sequence of SEQ ID NO: 2 and having a promoter activity,

c. a nucleotide sequence situated downstream of said promoter region and upstream of the translation initiation site, said nucleotide sequence comprising the 5′ untranslated region (5′ UTR) of the eukaryotic Initiation Factor 4G1 (elF4GI) gene, said 5′ UTR having the nucleotide sequence SEQ ID NO: 5, or a nucleic acid having at least 70% sequence identity with the sequence of SEQ ID NO: 5 and having mRNA stabilization and translation facilitator activitites, and

d. the intron of the Elongation Factor 1 a (EFla) gene having the nucleotide sequence SEQ ID NO: 10, or a nucleic acid having at least 70% sequence identity with the sequence of SEQ ID NO: 10, said intron being situated downstream of said 5′ UTR region and upstream of the transcription initiation site,

said transcription unit having the nucleotide sequence SEQ ID NO: 33, or a nucleotide add haying at least 70% sequence identity with the sequence SEQ ID NO: 33, and having said transcription activation activity, said promoter activity, and said mRNA stabilization and translation facilitator activity,

wherein said transcription unit is capable of generating a volume production of a protein of interest greater than that obtained with a combination of said CMVie virus enhancer combined with said promoter region of CDK9 alone.

2. An expression vector comprising at least one transcription unit as defined according to claim 1 and at least one cloning site allowing the integration of a nucleotide acid coding for a protein of interest.

3. An expression vector comprising at least one transcription unit as defined according to claim 1 and at least one site for the site-specific recombination allowing the integration of a nucleotide acid coding for a protein of interest.

4. The expression vector according to claim 2 , also comprising a eukaryotic resistance gene, a bacterial resistance gene, a bacterial origin of replication and a dedicated gene amplification unit.

5. The expression vector according to claim 2 , in which said protein of interest is chosen from the group constituted by the proteins participating in coagulation or an immunoglobulin, cytokines, hormones, growth factors or complement factors and any fusion protein.

6. A host cell comprising an expression vector as defined in claim 2 .

7. The host cell according to claim 6 , said host cell being the YB2/0 cell line.

8. An expression system comprising an expression vector as defined according to claim 2 and a host cell comprising said expression vector allowing the expression of a protein of interest encoded by a nucleotide acid.

Assignments (3)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2014
From: FONTAYNE, ALEXANDRE; COUTARD, FRANCOIS
To: LABORATOIRE FRANCAIS DU FACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 033096/0202 →
Priority Claims (1)
FR 11 59864 · Oct 28, 2011 · national
Continuity (1)
Related Publication 20140242638A1 · Aug 28, 2014